The Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion (“OPDP”) started 2025 with two Untitled Letters, one in February and one in March, potentially signaling more enforcement for the year. OPDP issued only five enforcement letters in 2023 and 2024, with a heavy focus on influencer marketing. However, on April 1, 2025,... READ MORE
The Calm Before the Storm: OPDP Released Two Untitled Letters Before HHS’s Reduction in Force, Now What?
Posted on April 17, 2025 in Health Law News
Published by: Hall Render
